|
1
|
Tse E and Kwong YL: How I treat NK/T-cell
lymphomas. Blood. 121:4997–5005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duechler M, Linke A, Cebula B, Shehata M,
Schwarzmeier JD, Robak T and Smolewski P: In vitro cytotoxic effect
of proteasome inhibitor bortezomib in combination with purine
nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J
Haematol. 74:407–417. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vega F, Lin P and Medeiros LJ: Extranodal
lymphomas of the head and neck. Ann Diagn Pathol. 9:340–350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferry JA, Fung CY, Zukerberg L, Lucarelli
MJ, Hasserjian RP, Preffer FI and Harris NL: Lymphoma of the ocular
adnexa: A study of 353 cases. Am J Surg Pathol. 31:170–184. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cho EY, Han JJ, Ree HJ, Ko YH, Kang YK,
Ahn HS, Ahn SD, Park CJ and Huh J: Clinicopathologic analysis of
ocular adnexal lymphomas: Extranodal marginal zone b-cell lymphoma
constitutes the vast majority of ocular lymphomas among Koreans and
affects younger patients. Am J Hematol. 73:87–96. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Charton J, Witherspoon SR, Itani K, Jones
FR, Marple B and Morse B: Natural killer/T-cell lymphoma
masquerading as orbital cellulitis. Ophthal Plast Reconstr Surg.
24:143–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dai W, Zhong M, Shen W, Zou K and Bai CG:
Natural killer T-cell lymphoma originating from the orbit. Chin Med
J (Engl). 125:1677–1680. 2012.PubMed/NCBI
|
|
8
|
Ennishi D, Maeda Y, Fujii N, Kondo E,
Shinagawa K, Ikeda K, Ichimura K, Yoshino T and Tanimoto M:
Allogeneic hematopoietic stem cell transplantation for advanced
extranodal natural killer/T-cell lymphoma, nasal type. Leuk
Lymphoma. 52:1255–1261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwong YL: Hematopoietic stem cell
transplantation in natural killer cell lymphoma and leukemia. Int J
Hematol. 92:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li M, Gao C, Li H, Wang Z, Cao Y, Huang W,
Li X, Wang S, Yu L and Da W: Allogeneic haematopoietic stem cell
transplantation as a salvage strategy for relapsed or refractory
nasal NK/T-cell lymphoma. Med Oncol. 28:840–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SJ and Kim WS: Treatment of localized
extranodal NK/T cell lymphoma, nasal type. Int J Hematol.
92:690–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chauchet A, Michallet AS, Berger F,
Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront
B, Petrella T, et al: Complete remission after first-line
radio-chemotherapy as predictor of survival in extranodal NK/T cell
lymphoma. J Hematol Oncol. 5:272012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH,
Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, et al: CHOP followed by
involved field radiation: Is it optimal for localized nasal natural
killer/T-cell lymphoma? Ann Oncol. 12:349–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Li XQ, Ma X, Hong X, Lu H and Guo
Y: Immunohistochemical expression and clinical significance of
P-glycoprotein in previously untreated extranodal NK/T-cell
lymphoma, nasal type. Am J Hematol. 83:795–799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamaguchi M, Kwong YL, Kim WS, Maeda Y,
Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, et al:
Phase II study of SMILE chemotherapy for newly diagnosed stage IV,
relapsed, or refractory extranodalnatural killer (NK)/T-cell
lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin
Oncol. 29:4410–4416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T,
Tse E, Leung AY and Chim CS: SMILE for natural killer/T-cell
lymphoma: Analysis of safety and efficacy from the Asia Lymphoma
Study Group. Blood. 120:2973–2980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hideshima T, Mitsiades C, Akiyama M,
Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi
NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating
antimyeloma activity of proteasome inhibitor PS-341. Blood.
101:1530–1534. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko
YH, Eom HS, Kim K, Park K and Kim WS: Phase I study of proteasome
inhibitor bortezomib plus CHOP in patients with advanced,
aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 19:2079–2083.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anderson VR and Perry CM: Fludarabine: A
review of its use in non-Hodgkin's lymphoma. Drugs. 67:1633–1655.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hewamana S, Alghazal S, Lin TT, Clement M,
Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett
AK, et al: The NF-kappaB subunit Rel A is associated with in vitro
survival and clinical disease progression in chronic lymphocytic
leukemia and represents a promising therapeutic target. Blood.
111:4681–4689. 2008. View Article : Google Scholar : PubMed/NCBI
|
